SOURCE: Alliqua BioMedical, Inc.

Alliqua BioMedical, Inc.

October 23, 2014 16:36 ET

Alliqua BioMedical, Inc. to Announce Third Quarter Financial Results on October 30th

The Company Will Host a Teleconference to Discuss the Results of the Quarter

LANGHORNE, PA--(Marketwired - Oct 23, 2014) - Alliqua BioMedical, Inc. (NASDAQ: ALQA) ("Alliqua" or "the Company"), a provider of advanced wound care products, today announced plans to release third quarter of fiscal 2014 financial results after market close on October 30th.

Chief Executive Officer, David Johnson, and Chief Financial Officer, Brian Posner, will host a teleconference at 5:00 p.m. Eastern Time on October 30th to discuss the results of the quarter and host a question and answer session. Those interested in participating on the call may dial 877-548-7901 (719-325-4838 for international callers) and provide access code 3177091 approximately 10 minutes prior to the start time. A live webcast of the call will be made available on the investor relations section of the Company's website at http://ir.alliqua.com.

For those unable to participate, a replay of the call will be available for two weeks at 888-203-1112 (719-457-0820 for international callers); access code 3177091. The webcast will be archived on the investor relations section of Alliqua's website.

About Alliqua BioMedical, Inc.

Alliqua is a provider of advanced wound care solutions. Through its sales and distribution network, together with its proprietary products, Alliqua provides a suite of technological solutions to enhance the wound care practitioner's ability to deal with the challenges of healing both chronic and acute wounds.

Alliqua currently markets its line of hydrogel products for wound care under the SilverSeal® and Hydress® brands, as well as the Sorbion sachet S® and Sorbion sana® wound care products, and its TheraBond 3D® advanced dressing which incorporates the TheraBond 3D® Antimicrobial Barrier Systems technology. It also markets the advanced wound care product Biovance®, as part of its licensing agreement with Celgene Cellular Therapeutics.

In addition, Alliqua can provide a custom manufacturing solution to partners in the medical device and cosmetics industry, utilizing its proprietary hydrogel technology. Alliqua's electron beam production process, located at its 16,000 square foot GMP manufacturing facility in Langhorne, PA, allows Alliqua to develop and custom manufacture a wide variety of hydrogels. Alliqua's hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for pharmaceutical and cosmetic industries.

For additional information, please visit http://www.alliqua.com. To receive future press releases via email, please visit http://ir.stockpr.com/alliqua/email-alerts.

Contact Information

  • Investor Relations:
    Westwicke Partners on behalf of Alliqua Biomedical, Inc.
    Mike Piccinino, CFA
    +1-443-213-0500
    Email Contact